IDXX · Idexx Laboratories Inc /De - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14B | - | $1.11B | $1.11B | $998.43M | - | $975.54M | $1.00B | $964.10M | - |
| Cost of Revenue | $418.08M | - | $379.50M | $384.42M | $375.05M | - | $379.50M | $384.42M | $371.02M | - |
| Gross Profit | $722.74M | - | $683.35M | $694.73M | $623.38M | - | $596.04M | $619.16M | $593.07M | - |
| R&D | $65.79M | - | $63.41M | $61.90M | $59.06M | - | $53.98M | $55.45M | $52.63M | - |
| SG&A | $119.11M | - | $105.94M | $98.68M | $91.56M | - | $91.89M | $157.24M | $92.02M | - |
| Total Operating Expenses | $360.15M | - | $292.15M | $355.36M | $294.11M | - | - | - | - | - |
| D&A | $37.68M | - | - | - | $34.06M | - | - | - | $29.90M | - |
| Operating Income | $362.59M | - | $354.85M | $373.05M | $316.53M | - | $303.89M | $263.80M | $298.96M | - |
| Interest Expense | $7.74M | - | $10.65M | $11.32M | $7.91M | - | $7.70M | $10.54M | $7.91M | - |
| Income Tax | $77.00M | - | $70.16M | $68.36M | $67.41M | - | $66.07M | $55.76M | $59.90M | - |
| Net Income | $278.45M | - | $274.61M | $293.99M | $242.68M | - | $232.84M | $203.30M | $235.58M | - |
| EPS - Basic | $3.50 | - | $3.43 | $3.66 | $2.98 | - | $2.83 | $2.46 | $2.84 | - |
| EPS - Diluted | $3.47 | - | $3.40 | $3.63 | $2.96 | - | $2.80 | $2.44 | $2.81 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $200.53M | $180.07M | $208.17M | $164.59M | $163.97M | $288.27M | $308.64M | $401.59M | $397.43M | $453.93M |
| Accounts Receivable | $603.54M | $552.38M | $566.88M | $560.56M | $527.46M | $473.57M | $511.25M | $533.61M | $507.21M | $457.44M |
| Inventory | $382.40M | $377.76M | $391.56M | $392.58M | $395.99M | $381.88M | $389.80M | $379.96M | $390.60M | $380.28M |
| Accounts Payable | $129.97M | $110.41M | $122.27M | $116.58M | $120.10M | $114.21M | $110.60M | $117.47M | $117.46M | $110.64M |
| Current Assets | $1.45B | $1.41B | $1.48B | $1.36B | $1.32B | $1.40B | $1.43B | $1.53B | $1.50B | $1.50B |
| Total Assets | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B | $3.29B | $3.35B | $3.41B | $3.35B | $3.26B |
| Current Liabilities | $1.30B | $1.15B | $1.25B | $1.22B | $1.14B | $1.07B | $1.01B | $1.12B | $956.90M | $951.55M |
| Long-term Debt | $299.85M | $374.84M | $374.82M | $449.81M | $449.80M | $449.79M | $524.76M | $524.74M | $620.78M | $622.88M |
| Total Liabilities | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B | $1.70B | $1.73B | $1.83B | $1.78B | $1.78B |
| Stockholders' Equity | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B | $1.60B | $1.62B | $1.58B | $1.57B | $1.48B |
| Retained Earnings | $6.67B | $6.39B | $6.14B | $5.87B | $5.58B | $5.33B | $5.12B | $4.88B | $4.68B | $4.44B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $266.25M | - | - | - | $237.96M | - | - | - | $198.59M | - |
| Investing Cash Flow | ($33.54M) | - | - | - | ($29.61M) | - | - | - | ($106.94M) | - |
| Financing Cash Flow | ($211.43M) | - | - | - | ($330.32M) | - | - | - | ($144.07M) | - |
| CapEx | $31.98M | - | - | - | $30.03M | - | - | - | $30.27M | - |
| Free Cash Flow | $234.26M | - | - | - | $207.94M | - | - | - | $168.31M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 63.4% | - | 61.8% | 62.6% | 62.4% | - | 61.1% | 61.7% | 61.5% | - |
| Operating margin | 31.8% | - | 32.1% | 33.6% | 31.7% | - | 31.2% | 26.3% | 31.0% | - |
| EBITDA margin | 35.1% | - | - | - | 35.1% | - | - | - | 34.1% | - |
| Net margin | 24.4% | - | 24.8% | 26.5% | 24.3% | - | 23.9% | 20.3% | 24.4% | - |
| Free cash flow margin | 20.5% | - | - | - | 20.8% | - | - | - | 17.5% | - |
| FCF / Net income | 0.84 | - | - | - | 0.86 | - | - | - | 0.71 | - |
| R&D / Revenue | 5.8% | - | 5.7% | 5.6% | 5.9% | - | 5.5% | 5.5% | 5.5% | - |
| SG&A / Revenue | 10.4% | - | 9.6% | 8.9% | 9.2% | - | 9.4% | 15.7% | 9.5% | - |
| Effective tax rate | 21.7% | - | 20.4% | 18.9% | 21.7% | - | 22.1% | 21.5% | 20.3% | - |
| Return on assets | 8.2% | - | 8.1% | 8.8% | 7.6% | - | 6.9% | 6.0% | 7.0% | - |
| Return on equity | 17.9% | - | 17.6% | 20.2% | 16.8% | - | 14.4% | 12.9% | 15.0% | - |
| Return on invested capital | 15.3% | - | 14.6% | 15.9% | 13.1% | - | 11.0% | 9.8% | 10.9% | - |
| Liquidity | ||||||||||
| Current ratio | 1.12 | 1.23 | 1.18 | 1.11 | 1.16 | 1.31 | 1.42 | 1.37 | 1.57 | 1.57 |
| Quick ratio | 0.82 | 0.90 | 0.87 | 0.79 | 0.81 | 0.95 | 1.03 | 1.03 | 1.16 | 1.17 |
| Cash ratio | 0.15 | 0.16 | 0.17 | 0.13 | 0.14 | 0.27 | 0.31 | 0.36 | 0.42 | 0.48 |
| Leverage | ||||||||||
| Debt / Equity | 0.19 | 0.23 | 0.24 | 0.31 | 0.31 | 0.28 | 0.32 | 0.33 | 0.40 | 0.42 |
| Debt / Assets | 0.09 | 0.11 | 0.11 | 0.14 | 0.14 | 0.14 | 0.16 | 0.15 | 0.19 | 0.19 |
| Debt / EBITDA | 0.75 | - | - | - | 1.28 | - | - | - | 1.89 | - |
| Interest coverage | 46.8x | - | 33.3x | 33.0x | 40.0x | - | 39.5x | 25.0x | 37.8x | - |
| Equity multiplier | 2.18 | 2.09 | 2.17 | 2.28 | 2.22 | 2.06 | 2.07 | 2.16 | 2.14 | 2.20 |
| Liabilities / Assets | 0.54 | 0.52 | 0.54 | 0.56 | 0.55 | 0.52 | 0.52 | 0.54 | 0.53 | 0.54 |
| Efficiency | ||||||||||
| Asset turnover | 0.34 | - | 0.33 | 0.33 | 0.31 | - | 0.29 | 0.29 | 0.29 | - |
| Inventory turnover | 1.09 | - | 0.97 | 0.98 | 0.95 | - | 0.97 | 1.01 | 0.95 | - |
| Days sales outstanding | 193d | - | 187d | 184d | 193d | - | 191d | 194d | 192d | - |
| Days inventory outstanding | 334d | - | 377d | 373d | 385d | - | 375d | 361d | 384d | - |
| Days payable outstanding | 113d | - | 118d | 111d | 117d | - | 106d | 112d | 116d | - |
| Cash conversion cycle | 413d | - | 446d | 446d | 461d | - | 460d | 443d | 461d | - |
| Valuation | ||||||||||
| P / E | 161.9x | - | 187.9x | 147.8x | 141.9x | - | 180.4x | 199.7x | 192.1x | - |
| P / B | 28.9x | - | 33.0x | 29.8x | 23.8x | - | 25.9x | 25.7x | 28.9x | - |
| P / S | 39.5x | - | 46.6x | 39.2x | 34.5x | - | 43.0x | 40.5x | 47.0x | - |
| EV / EBITDA | 112.8x | - | - | - | 98.9x | - | - | - | 138.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 14.3% | - | 13.3% | 10.6% | 3.6% | - | 6.6% | 6.4% | 7.1% | - |
| Revenue CAGR (3y) | 8.2% | - | 9.5% | 8.8% | 6.1% | - | 6.4% | 6.7% | 7.4% | - |
| Revenue CAGR (5y) | 8.0% | - | 8.9% | 11.7% | 9.8% | - | 10.0% | 10.1% | 10.8% | - |
| Gross profit growth (YoY) | 15.9% | - | 14.6% | 12.2% | 5.1% | - | 8.8% | 8.1% | 9.2% | - |
| Operating income growth (YoY) | 14.5% | - | 16.8% | 41.4% | 5.9% | - | 10.4% | -10.9% | 6.6% | - |
| Net income growth (YoY) | 14.7% | - | 17.9% | 44.6% | 3.0% | - | 9.7% | -9.3% | 10.1% | - |
| EPS growth (YoY) | 17.2% | - | 21.4% | 48.8% | 5.3% | - | 10.7% | -8.6% | 10.2% | - |
| EPS CAGR (3y) | 10.8% | - | 16.5% | 32.5% | 9.3% | - | 11.3% | 1.4% | 6.1% | - |
| EPS CAGR (5y) | 8.1% | - | 15.0% | 16.1% | 18.1% | - | 17.7% | 11.3% | 19.2% | - |
| FCF growth (YoY) | 12.7% | - | - | - | 23.5% | - | - | - | 16.6% | - |
| FCF CAGR (5y) | 17.6% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 7.5% | 0.6% | -3.5% | -7.7% | -7.7% | 7.5% | 24.7% | 44.5% | 86.5% | 143.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$4.29B totalCompanion Animal Group Segment$3.95B · 92.2%
Water Segment$201.15M · 4.7%
Livestock And Poultry Diagnostics Segment$131.79M · 3.1%
Product / service
$12.01B totalCAGDiagnostics Recurring Revenue$3.41B · 28.4%
Product$2.54B · 21.1%
Service$1.76B · 14.7%
Vet Lab Consumables$1.50B · 12.5%
Reference Laboratory Diagnostic And Consulting Services$1.42B · 11.9%
Rapid Assay Products$348.95M · 2.9%
Veterinary Software Services And Diagnostic Imaging Systems$345.88M · 2.9%
Recurring Revenue$276.34M · 2.3%
CAGDiagnostic Capital Instruments$200.21M · 1.7%
CAGDiagnostics Service And Accessories$137.42M · 1.1%
Systems And Hardware$69.54M · 0.6%
Geographic
$8.61B totalAmericas$3.01B · 35.0%
US$2.75B · 32.0%
EMEA$937.25M · 10.9%
Asia Pacific$355.93M · 4.1%
Europethe Middle Eastand Africa Other$230.03M · 2.7%
DE$206.76M · 2.4%
CA$167.32M · 1.9%
GB$154.44M · 1.8%
FR$126.00M · 1.5%
Asia Pacific Other$124.36M · 1.4%
AU$112.25M · 1.3%
Latin America And Caribbean$90.41M · 1.1%
JP$83.36M · 1.0%
ES$70.97M · 0.8%
IT$66.86M · 0.8%
CH$41.70M · 0.5%
NL$40.50M · 0.5%
CN$35.96M · 0.4%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing IDEXX LABORATORIES INC /DE against the 5 most active filers in the same SIC group.